Abiopharma

🔍 Crystal Adam (Executive)

Company: Tango Therapeutics, Inc. (TNGX)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 27,000 shares of Common Stock at $5.2 per share (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: false | shares_owned_after: 139,622.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 27,000 shares of Common Stock at $21.2029 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: false | shares_owned_after: 112,622.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 27,000 shares of Stock Option (Right to Buy) at $5.2 per share (Derivative)
  Date: 2026-04-01 | Code: M | Expires: 2033-03-01 | equity_swap_involved: false | shares_owned_after: 433,500.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
• F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.69, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
• F3: This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.